Clinical Research Directory
Browse clinical research sites, groups, and studies.
Human Umbilical Cord-mesenchymal Stem Cells Via Different Transplantation Routes in ESLD
Sponsor: General Hospital of Shenyang Military Region
Summary
Stem cells are non-terminal cells that can self renew and replicate through symmetric or asymmetric division, with the potential to differentiate into different types of cells and tissues. Multiple studies have shown that human umbilical cord mesenchymal stem cell has good safety and effectiveness in improving acute or chronic liver injury. Stem cell therapy for end-stage liver disease (ESLD) can be administered through various routes, among which hepatic artery and peripheral vein infusions are the most commonly used in clinical practice. The efficacy of hepatic artery infusion appears to be greater than that of peripheral vein infusion.
Official title: Efficacy and Safety of Different Transplantation Routes of Human Umbilical Cord-mesenchymal Stem Cells in Patients With End-stage Liver Disease
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
32
Start Date
2025-09
Completion Date
2027-12
Last Updated
2025-08-24
Healthy Volunteers
No
Conditions
Interventions
Infusion of umbilical cord-mesenchymal stem cells through peripheral veins
Umbilical cord-mesenchymal stem cells injected through peripheral veins
Infusion of umbilical cord-mesenchymal stem cells through hepatic artery
Umbilical cord-mesenchymal stem cells injected through hepatic artery
Locations (1)
General Hospital of Northern Theater Command Recruiting
Shenyang, Liaoning, China